Retension Pharmaceuticals, Inc.
Retension Pharmaceuticals CEO Eric Keller reported a 7.07% stake in the company's common stock via a Schedule 13D filing on Oct. 14, 2026. The stake includes founder shares, option grants, and IPO-related conversions. Keller plans to stay engaged in strategy and governance, with potential to buy or sell shares post a 180-day IPO lock-up. He has led the company since 2023.
Keller Eric L. (CHIEF EXECUTIVE OFFICER) purchased 20,800 shares of Retension Pharmaceuticals, Inc. (RTSN) at $12.00 ($0.25M total) on 2026-10-13.
BERGER FRANKLIN M purchased 10,000 indirectly-held shares of Retension Pharmaceuticals, Inc. (RTSN) at $12.00 ($0.12M total) on 2026-10-13.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning RTSN (Retension Pharmaceuticals, Inc.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent RTSN coverage spans insider activity, financial news and market movers.
In the last 30 days, RTSN insiders filed 2 SEC Form 4 transactions — 2 purchases ($370K) and no sales. The most active reporter was Keller Eric L., CHIEF EXECUTIVE OFFICER, with 1 filing.
The filing reveals a sizable insider position, suggesting confidence in the company and potentially supporting the stock price.
Insider purchase by the CEO signals confidence and may provide modest upward pressure on the stock.
The insider purchase may signal confidence from management, providing modest positive pressure on the stock.
IPO momentum may sustain short‑term buying interest.
AlphAI scores every news story that mentions RTSN with an AI model for sentiment and relevance, and aggregates insider trades from Retension Pharmaceuticals, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Retension Pharmaceuticals CEO Eric Keller reported a 7.07% stake in the company's common stock via a Schedule 13D filing on Oct. 14, 2026. The stake includes founder shares, option grants, and IPO-related conversions. Keller plans to stay engaged in strategy and governance, with potential to buy or sell shares post a 180-day IPO lock-up. He has led the company since 2023.
1 min readKeller Eric L. (CHIEF EXECUTIVE OFFICER) purchased 20,800 shares of Retension Pharmaceuticals, Inc. (RTSN) at $12.00 ($0.25M total) on 2026-10-13.
1 min readBERGER FRANKLIN M purchased 10,000 indirectly-held shares of Retension Pharmaceuticals, Inc. (RTSN) at $12.00 ($0.12M total) on 2026-10-13.
1 min readBiotech stocks BIIB, RTSN, CON, HNGE, and HSTM reached 52-week highs on October 12, 2026. BIIB hit $230.49 after positive clinical data for Litifilimab. RTSN rose 7% to $11.32 post-IPO. CON reported Q2 revenue growth of 10% to $606M. HNGE saw Q2 revenue rise 53% to $212M and acquired Cylinder Health. HSTM's Q2 revenue grew 12.5% to $83.7M.
2 min read
